Bioheng Raised $80 Million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies
Release Time:
2021-03-25
Source:
Reprint to:
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing. The Series B was co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures China and Shenzhen Capital Group Company.
Lu Han, Founder and Chief Executive Officer of Bioheng, stated, " We are thrilled to get recognition from such an excellent group of biotech investors and proud of the continued support from existing shareholders. Bioheng focuses on the development of allogeneic immuno-cell therapy. At present, we have made progress in several indications with promising clinical data. Proceeds from this financing will continue to be used to advance R&D capabilities, process development and clinical trials. We are looking forward to providing more affordable 'off-the-shelf' immuno- cell therapies to patients soon. "
"It is a great honor to continue supporting Bioheng in Series B financing. We have strong confidence in company's technologies and management team," said Dr. Xiangmin Cui, Founder and Managing Director of Decheng Capital. "In the past two years, company has enriched the pipeline and made solid progress in multiple assets' clinical development, demonstrating strong research and development capabilities."
Dr. Ting Jia, Founder and Chief Investment Officer of Octagon Capital, expressed, "Bioheng has a clear scientific vision, an outstanding teamwork spirit and unswerving sense of innovation. We are excited to have the opportunity to work with such an excellent team and will accompany them for a long journey."
Related News
June 1, 2025 , Bioheng Therapeutics, an innovative biopharmaceutical company focused on the development and commercialization of cell therapies, presented results from an investigator-initiated trial (IIT) of RD06-03, its allogeneic anti-CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
February 28, 2025 – Bioheng Therapeutics US LLC (“Bioheng”), a clinical-stage biopharmaceutical company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for CTD402, a CD7-targeted universal CAR-T (UCAR-T) cell therapy, for the treatment of pediatric and adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). The study approved by the FDA is a single-arm, open-label Phase Ib/II trial with a simplified dose-finding design, designed to optimize dosing and accelerate clinical development.
November 7, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company dedicated to the development and commercialization of cell therapy products, announced today that it will present the latest Phase I clinical data of its universal CAR-T cell product RD13-02, targeting CD7 for the treatment of relapsed/refractory(R/R) T-ALL/LBL patients, in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting. The conference will take place from December 7-10, 2024, in San Diego, USA.
On May 16, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company focusing on the development and commercialization of Universal Chimeric Antigen Receptor T-cell (UCAR-T) products, announced today that it will present the Phase I clinical data of its CD7-targeted Universal CAR-T cell product, RD13-02, for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) patients at the 29th European Hematology Association (EHA 2024) Annual Congress, to be held in Madrid, Spain, from June 13 to 16, 2024, in the form of an academic poster.
On April 25, 2024, The New England Journal of Medicine published the latest findings by the team of He Huang, M.D., PhD., and Yongxian Hu, M.D., PhD., from the First Affiliated Hospital, Zhejiang University School of Medicine, titled "Sequential CD7 CAR-T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis"[1]. The study introduces an innovative treatment strategy that combines CD7 CAR-T with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the first time.
Bioheng Received CDE IND Approval for CTA101 UCAR-T
On March 17,2022, China National Drug Administration Drug Review Center ( CDE ) approved first Universal Chemeric Antigen Receptor T (UCAR-T) cell drug ( Acceptance No. : CXSL2101509 ) . CTA101 is independently developed by Nanjing Bioheng Biotech Co., Ltd ( hereinafter referred as ' Bioheng), targeting CD19 and CD22, for the indication of adult recurrent or refractory B-cell acute lymphoblastic leukemia ( r / r B-ALL ).
Contact Us